Navigation Links
Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico
Date:1/7/2009

New office will provide marketing support to improve awareness and knowledge of Daiichi Sankyo's innovative treatments

PARSIPPANY, N.J., Jan. 7 /PRNewswire/ -- Daiichi Sankyo, Inc., announced today that it has established a subsidiary -- Daiichi Sankyo de Puerto Rico, Inc. Daiichi Sankyo de Puerto Rico, Inc. is based in San Juan, and led by Jose Vazquez, Regional Director -- Puerto Rico, who has more than 20 years of experience in pharmaceutical sales and marketing. Vazquez, who earned his Bachelor of Arts degree in Biology and Juris Doctor from the University of Puerto Rico, has assembled an experienced team of sales representatives and marketing professionals with many years of experience and deep knowledge of the local market in Puerto Rico.

"We are excited about the opening of this new office in Puerto Rico. Our presence here enables us to establish close ties with healthcare partners throughout Puerto Rico and to directly support our customers with educational materials and managed care programs," said Vazquez. "The opening of this office is another indication of the growth of Daiichi Sankyo, which is fueled by our expanding portfolio of marketed products, as well as by our robust pipeline of promising new compounds. The new office in San Juan will ensure that our Puerto Rico customers have direct access to information about these innovative products."

Daiichi Sankyo de Puerto Rico, Inc., as a sales agent for Daiichi Sankyo, Inc. in Puerto Rico, will provide the local medical community and their patients direct access to materials and information about Daiichi Sankyo, Inc.'s products that address medical needs in cardiovascular and diabetes care. Daiichi Sankyo's current portfolio of marketed products is focused on hypertension, cholesterol and type 2 diabetes. The current focus of Daiichi Sankyo's research and development is cardiovascular and metabolic disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Daiichi Sankyo is also pursuing the discovery of new medicines in the areas of thrombosis, cancer, diabetes, and autoimmune disease/rheumatoid arthritis.

The new Daiichi Sankyo de Puerto Rico, Inc. office is located at The Atrium Office Center, 530 Avenida de la Constitucion, Office Number 258, Puerta de Tierra, San Juan, Puerto Rico 00901-2304. The office's main telephone number is 787-289-8700.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit

www.dsus.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program
2. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
3. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
4. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
5. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
6. Cystic Fibrosis Foundation Establishes Landmark Patient Assistance Foundation
7. Body-Jet Water-Assisted Liposuction Establishes New Standard for Liposuction and Fat Harvesting
8. Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc.
9. Halleland Health Consulting Establishes URAC Accreditation Program
10. Jenny Craig Establishes License Agreement for Volumetrics(R)
11. Disabled Veteran Establishes Non-Profit, AVHRT, to House Injured Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... According to ... In an industry filled with chemical-laden beauty products, one company is going against the ... for you: Mad Hippie. The rising star in the green space is proud to ...
(Date:5/26/2016)... Lake MN (PRWEB) , ... May 26, 2016 , ... ... Stance Angle chair , furniture that may support women during pregnancy. Potential benefits ... legs and feet, improved rest and comfort and healthier levels of sitting and standing. ...
(Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The United ... treatment of androgenetic alopecia in both men and women. To date, the company is ... with FDA clearance for any adult who suffers with androgenetic alopecia. , “This ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
Breaking Medicine Technology: